VXRT
Vaxart, Inc.
0.90
-
0.02
2.64%
2 x 0.88
10 x 0.91
bid
ask
6 @ 04:00 PM
0.93+0.03 (3.32%)
Bearish
93
Bullish
294
sentiment
0.90
day range
0.95
0.52
52 week range
1.54
News
...
Does Vaxart Inc (VXRT) offer a good opportunity for investors? | news.google.com • |
Vaxart (NASDAQ:VXRT) Shares Cross Above Two Hundred Day Moving Average of $0.85 | news.google.com • |
VXRT (Vaxart Inc) may reap gains as insiders became active recently | news.google.com • |
Checking in on Travere Therapeutics Inc (TVTX) after recent insiders movement | news.google.com • |
VTLE’s latest rating updates from top analysts. | news.google.com • |
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics | news.google.com • |
Profile
...
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | -0.1 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | 0.03 | -0.09 | -0.12 | -400.00% |
2024-05-13 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2024-06-10 | FINNEY MICHAEL J | Director | 686.84K | Stock Award(Grant) |
2024-06-10 | HERON ELAINE J | Director | 40.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend
...
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split
...
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
This topic has been deleted. Only users with topic management privileges can see it.
-
WSB is finally here to burn the shorts...let’s go
-
-
-
-
-
-
-
-
-
-
-
PSA:
$VXRT presenting at world vaccine conference at 5:00 EST.Company said yesterday their results blow away all other vaccines and defend against variants
Company said yesterday the pretty much found the cure for the common cold and have a flu vaccine that will end the need for flu shots
If you are too lazy to do your own DD, if you’re too stupid to understand what you have, if all you do is react to posts in an F’n chat… please sell and leave or turn on Sesame Street and follow along with their lessons…
-
-
-
Does Vaxart Inc (VXRT) offer a good opportunity for investors?
news.google.com • -
VXRT (Vaxart Inc) may reap gains as insiders became active recently
news.google.com • -
VTLE’s latest rating updates from top analysts.
news.google.com • -
Financial Snapshot: Analyzing Vaxart Inc (VXRT)’s Key Ratio Metrics
news.google.com • -
Is Vaxart Inc (VXRT) a good investment opportunity?
news.google.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
seekingalpha.com • -
Vaxart Provides Business Update
globenewswire.com • -
Vaxart Announces $40 Million Underwritten Offering of Common Stock
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
globenewswire.com • -
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com •